Viatris’s Pacira Deal Buys Established Pain Medicines, but Growth Must Justify the Price

Viatris has agreed to acquire Pacira BioSciences for $36.50 per share in cash, representing $1.65 billion of aggregate equity value. The October 8 agreement adds EXPAREL for postsurgical pain and ZILRETTA for osteoarthritis knee pain, alongside commercial and development capabilities that support Viatris’s move into innovative medicines.

For Pacira shareholders, the proposed transaction exchanges future product and pipeline exposure for a defined cash consideration, subject to closing. For Viatris shareholders, it creates a different test: whether existing earnings, product longevity and broader distribution generate adequate returns on the purchase price. Established products reduce development-stage uncertainty, but they still require pricing discipline, sustained demand and control of operating costs.

An operating platform with concentrated revenue

The joint announcement reports approximately $746 million of revenue and $177 million of adjusted EBITDA for Pacira over the twelve months ended June 30, 2026. Those figures imply a 23.7% adjusted EBITDA margin. Viatris is acquiring a revenue-generating platform with cash-producing products, while taking responsibility for maintaining their commercial position.

Pacira’s second-quarter results show where that platform is concentrated. EXPAREL generated $147.8 million of quarterly sales and ZILRETTA $32.6 million, together accounting for approximately 93.8% of total revenue of $192.4 million. The remaining revenue included other product sales and royalties, including iovera before its disposal.

Concentration makes the investment case relatively legible. Small changes in EXPAREL’s growth, contracting or competitive position can have a larger effect on acquisition returns than progress in a smaller pipeline program. International expansion could diversify the revenue base geographically, but it would initially extend exposure to the same underlying products.

Equity value is only the starting point

Dividing the announced equity price by trailing revenue gives 2.21 times sales, while dividing it by adjusted EBITDA gives 9.32 times. These are equity-price comparisons, not enterprise-value acquisition multiples. An operating-business valuation must also account for debt and acquired liquidity, with the final treatment governed by closing arrangements.

Pacira’s June 30 filing reported $287.5 million of convertible-note principal, $81 million drawn on its revolver and $251 million of cash and investments. Using those historical balances produces the following illustrative bridge, before fees, debt-settlement effects or later changes.

The bridge is a historical reference, not the announced enterprise value or a forecast of closing cash requirements. Pacira subsequently received $73.6 million when it sold iovera to Zimmer on July 31, and operating cash flows since June also change liquidity. The revolver’s $300 million commitment is facility capacity; only the $81 million actually drawn belongs in the June debt calculation.

The acquired earnings perimeter has changed

The iovera disposal creates a second issue for the trailing multiples: historical revenue includes a business that Viatris will not acquire. Pacira’s updated annual guidance explicitly includes iovera revenue only through its July closing date. Historical cash from the disposal and historical earnings from the disposed operation affect opposite sides of a valuation assessment.

A cleaner acquisition model would use the continuing portfolio’s earnings and a closing balance sheet, then incorporate integration spending and any debt-settlement costs. The trailing figures remain useful for scale, but they cannot establish the continuing business’s exact acquisition multiple. Removing revenue alone would also be insufficient because the disposed operation’s expenses and associated corporate costs must be considered.

Adjusted earnings need similar care. Pacira reported second-quarter GAAP net income of $4.7 million versus adjusted EBITDA of $48.7 million. Its reconciliation includes interest, tax, depreciation and amortization, plus adjustments such as stock compensation and transaction expenses. Adjusted EBITDA can describe operating capacity, while cash returns still depend on capital expenditure, working capital, taxes and continuing economic costs.

Product growth has to survive commercial trade-offs

EXPAREL’s second-quarter volume increased 4%, while sales rose about 3%. Pacira attributed the difference partly to vial mix and expanded group-purchasing discount programs. This illustrates the commercial trade-off behind broader access: more procedures or units do not necessarily produce equivalent revenue growth.

For Viatris, distribution scale may help increase adoption and enter selected international markets. The return on that effort depends on the incremental revenue retained after discounts, local market-access costs and commercial spending. A larger footprint creates an opportunity, but the benefit needs to appear in contribution profit and cash flow.

ZILRETTA adds another marketed product, with a different pain setting, while the pipeline supplies longer-duration optionality. The base acquisition case is easier to defend when it relies on durable cash from marketed medicines. Development programs can provide upside, but their future value should reflect the capital and clinical work still required before commercialization.

Funding fits Viatris’s scale, with a cash opportunity cost

Viatris expects to finance the purchase primarily with excess cash and the remainder with short-term borrowings. Management anticipates minimal impact on gross leverage and immediate accretion to its financial guidance metrics. Those are management expectations; the announcement does not provide a quantified synergy target or a detailed post-acquisition earnings bridge.

The buyer’s August financial outlook provides perspective. Viatris guided to $14.55 billion to $14.95 billion of 2026 revenue and $4.3 billion to $4.5 billion of adjusted EBITDA. Pacira’s trailing revenue is approximately 5.1% of the revenue midpoint, while its trailing adjusted EBITDA is approximately 4.0% of Viatris’s adjusted EBITDA midpoint. These comparisons mix historical target figures with buyer forecasts and indicate scale, not a combined-company forecast.

Using cash can limit new borrowing while still consuming financial flexibility. Acquisition returns must therefore compete with debt reduction, shareholder distributions and other investments. Immediate accretion is useful, but it does not by itself demonstrate a return above the buyer’s cost of capital.

What to watch before and after closing

The companies expect completion by year-end 2026 through a tender offer followed by a merger. Closing requires a majority of Pacira shares to be tendered and the applicable regulatory waiting period to expire, among other conditions. The offer remains a pending transaction until those requirements are satisfied.

For Viatris, subsequent disclosures should connect the purchase price to continuing-product cash generation, debt treatment and integration costs. Product-level growth, discounting and international launch economics will help test the commercial thesis. For Pacira holders, tender documentation and closing progress determine realization of the cash consideration.

The deal adds established medicines to Viatris’s innovative portfolio without making its future returns automatic. A purchase near ten times trailing adjusted EBITDA on the illustrative June balance-sheet bridge could be supported by durable cash generation and measured expansion. That case becomes firmer when continuing-business earnings, acquisition costs and realized growth can be assessed on the same perimeter.